Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Neoplasm predisposition characterized by an increased risk of paragangliomas (tumors that arise from neuroendocrine tissues distributed along the paravertebral axis from the base of the skull to the pelvis) and pheochromocytomas (paragangliomas that are confined to the adrenal medulla).
Biomarker and diagnostic research for hereditary pheochromocytoma-paraganglioma has been reported in the published literature.
Estimated prevalence: 1-9 in 1,000,000 (Rare).
1 clinical trial registered, 1 recruiting. Interventions under study include other interventions. Research is primarily sponsored by academic and government institutions.
17 publications have been identified in PubMed for hereditary pheochromocytoma-paraganglioma. Research spans Case Report / Case Series (41%), Review / Meta-Analysis (35%), and Basic Science / Preclinical (12%).
Research Type | Count | % of Total |
|---|---|---|
Patient case studies | 7 | 41% |
Data assembled from 4 of 12 sources · Last updated Sep 20, 2026, 5:36 PM UTC
European rare disease database
Genetic and Rare Diseases Info Center
Research summaries |
6 |
35% |
Laboratory research | 2 | 12% |
Testing and diagnosis research | 1 | 6% |
Disease patterns and progression | 1 | 6% |
Ornstead MJ (2026). [PMID: 41985045](https://pubmed.ncbi.nlm.nih.gov/41985045/). *Int J Surg Pathol*. [Basic Science / Preclinical]
Nakamura R (2026). [PMID: 42005593](https://pubmed.ncbi.nlm.nih.gov/42005593/). *IJU Case Rep*. [Case Report / Case Series]
Cornejo KM (2026). [PMID: 41622805](https://pubmed.ncbi.nlm.nih.gov/41622805/). *Adv Anat Pathol*. [Review / Meta-Analysis]
Bayley JP (2026). [PMID: 41915642](https://pubmed.ncbi.nlm.nih.gov/41915642/). *PLoS One*. [Basic Science / Preclinical]
Saleh Y (2025). [PMID: 41341087](https://pubmed.ncbi.nlm.nih.gov/41341087/). *Proc (Bayl Univ Med Cent)*. [Case Report / Case Series]
Rednam SP (2025). [PMID: 40549645](https://pubmed.ncbi.nlm.nih.gov/40549645/). *Clin Cancer Res*. [Review / Meta-Analysis]
Nose V (2025). [PMID: 40179837](https://pubmed.ncbi.nlm.nih.gov/40179837/). *Acta Cytol*. [Review / Meta-Analysis]
Mertiri L (2025). [PMID: 41029896](https://pubmed.ncbi.nlm.nih.gov/41029896/). *J Neuroimaging*. [Review / Meta-Analysis]
Florou V (2025). [PMID: 39927693](https://pubmed.ncbi.nlm.nih.gov/39927693/). *Cancer Med*. [Review / Meta-Analysis]
Charbel C (2025). [PMID: 41284030](https://pubmed.ncbi.nlm.nih.gov/41284030/). *Abdom Radiol (NY)*. [Review / Meta-Analysis]